Evotec (NASDAQ:EVO) Lowered to “Hold” Rating by Berenberg Bank

Evotec (NASDAQ:EVO) was downgraded by Berenberg Bank from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Other equities research analysts have also recently issued research reports about the stock. TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective on the stock. in a research note on Wednesday. HC Wainwright lowered their price target on shares of Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday. Wall Street Zen lowered shares of Evotec from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Weiss Ratings raised shares of Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.00.

Evotec Stock Performance

Shares of Evotec stock opened at $2.01 on Thursday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.68 and a quick ratio of 1.60. The firm has a fifty day moving average price of $2.79 and a 200 day moving average price of $3.03. Evotec has a 1 year low of $1.97 and a 1 year high of $4.41.

Evotec (NASDAQ:EVO) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $0.05 earnings per share (EPS) for the quarter. The business had revenue of $297.02 million during the quarter. Evotec had a negative return on equity of 24.93% and a negative net margin of 26.20%. Equities research analysts anticipate that Evotec will post -0.63 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in EVO. Apollon Wealth Management LLC acquired a new stake in Evotec in the 1st quarter valued at $28,000. Marshall Wace LLP acquired a new position in Evotec during the fourth quarter worth $40,000. SmartHarvest Portfolios LLC purchased a new position in Evotec during the first quarter valued at $44,000. BNP Paribas Financial Markets grew its position in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after purchasing an additional 4,600 shares during the period. Finally, Bank of America Corp DE grew its position in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after purchasing an additional 9,289 shares during the period. 5.81% of the stock is owned by institutional investors and hedge funds.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.